NGLFINE.NS NGL Fine-Chem (NSE) +20.00% pre-market 05 Feb 2026: earnings catalyst to watch

NGLFINE.NS stock rallied 20.00% in pre-market trade to INR 2,164.20 on 05 Feb 2026 as investors priced an earnings catalyst. We see volume at 26,215 shares, nearly nine times average, signalling genuine demand rather than a blip. In this report we link the price move to company fundamentals, sector context and technical signals, and give clear price scenarios ahead of the 05 Feb 2026 earnings release.

Price action and trading signals for NGLFINE.NS stock

NGL Fine-Chem (NGLFINE.NS) opened pre-market at INR 2,050.00 and hit a high of INR 2,164.20. The one-day change is +20.00% from the previous close of INR 1,803.50. Volume surged to 26,215 versus an average of 2,984, giving a relative volume of 8.78. Short-term indicators show RSI 55.54 and ADX 25.97, which point to an active uptrend but not an extended overbought condition across technicals.

Fundamentals and valuation: EPS, PE and balance-sheet metrics

NGL Fine-Chem reports EPS 57.17 and a trailing PE of 37.86 on the NSE in India. Market cap stands at INR 13,370,479,541.00 with book value per share INR 485.91 and price-to-book 4.45. Current ratio is 1.90 and debt-to-equity 0.29, showing moderate leverage. Gross margin near 50.92% supports pricing power in the drug manufacturers sector.

Meyka AI grade and model outlook for NGLFINE.NS stock

Meyka AI rates NGLFINE.NS with a score out of 100: 71.82 (Grade B+, Suggestion: BUY). This grade factors S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecasts and analyst consensus. Meyka AI’s forecast model projects a 12-month price near INR 1,491.94, implying -31.07% versus the current INR 2,164.20. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.

Technical setup and short-term targets for NGLFINE.NS stock

Technicals show MACD histogram positive with MACD 26.05 and signal 10.07, and Money Flow Index 81.54 indicating heavy inflows. Bollinger middle band is INR 1,363.24 and ATR 62.60, which suggests wider price swings. Conservative short-term target: INR 2,400.00 (≈10.90% upside). Bull case target using PE expansion to 45 yields INR 2,572.65 (≈18.88% upside).

Sector context, catalysts and risks for NGLFINE.NS stock

NGL Fine-Chem sits in India’s Healthcare sector, where average PE is 38.21. The stock’s earnings announcement on 05 Feb 2026 is the clear catalyst behind the pre-market jump. Upside catalysts include stronger animal-health exports and margin recovery. Risks include volatile raw material costs, slower operating income growth, and valuation re-rating if earnings miss guidance.

Analyst view, liquidity and trading considerations

Market consensus on formal broker upgrades is limited; internal company metrics show a trailing twelve-month price average INR 1,432.64 (50-day) and INR 1,339.85 (200-day). Average daily volume before the move was 2,984, so liquidity can thin outside event windows. Traders should use stop-losses and position sizing given the faster moves and a cash-per-share cushion of INR 103.15 on the balance sheet.

Final Thoughts

Key takeaways on NGLFINE.NS stock: the pre-market +20.00% move to INR 2,164.20 reflects an earnings-driven momentum trade ahead of the 05 Feb 2026 report. Fundamentals show solid margins, EPS 57.17, and manageable leverage, but valuation is full with PE 37.86. Meyka AI’s model projects INR 1,491.94 over twelve months, implying -31.07% from today; that is a model-based downside scenario and not a guarantee. We present a balanced view: a short-term trading target of INR 2,400.00 and a bull target of INR 2,572.65 if earnings beat and sector multiples expand. Watch actual results, management commentary, and export demand. Meyka AI, our AI-powered market analysis platform, flags both opportunity and risk; traders should size positions and use clear exit rules.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.